Cannara Biotech Inc. Experiences Q1 2023 Monetary Outcomes

Firm recorded $10.3 million in quarterly income; a 57% enhance in comparison with Q1 2022

Delivered its seventh consecutive quarter of constructive Adjusted EBITDA of $1.7M and reported constructive internet revenue for a second consecutive quarter

Continued to extend rising capability to satisfy buyer demand by activating new rising zone in its increasing Valleyfield Facility

All monetary outcomes are reported in Canadian {dollars}, until in any other case said.

MONTREAL, Jan. 23, 2023 /CNW/ – Cannara Biotech Inc. (“Cannara” or the “Firm“) (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB), a vertically built-in producer of premium-grade hashish and by-product product choices at reasonably priced costs  with two mega amenities primarily based in Québec spanning over 1,650,000 sq. ft., right now introduced its fiscal first quarter 2023 monetary and working outcomes for the three-month interval ended November 30, 2022.

Fiscal First Quarter 2023 Monetary Highlights

• Q1 2023 income of $10.3 million, an 57% enhance in comparison with Q1 2022.

• Recorded Q1 2023 gross revenue earlier than truthful worth changes of $4 million, a rise of 34% in comparison with Q1 2022.

• Delivered the Firm’s seventh straight quarter of constructive Adjusted EBITDA of $1.7 million, a 72% enhance in comparison with Q1 2022.

• Earned internet revenue of $2,951 for Q1 2023.

• The Firm has $27.1 million in working capital as of November 30, 2022, which incorporates $6.8 million of money readily available.

Fiscal First Quarter 2023 Gross sales and Operational Highlights

• Cannara activated its seventh of 24 particular person 25,000 sq. foot rising zones at its Valleyfield Facility, reaching a complete of 175,000 sq. toes of energetic cover. Mixed with its Farnham Facility, the Firm can presently produce roughly 23,500 kg of premium-grade hashish per yr and has a possible future capability of 120,000 kg of premium-grade hashish per yr when each Services are totally constructed out.

• The Firm has set an goal for fiscal 2023 of activating 9 rising zones, a 50% enhance from the capability the Valleyfield Facility was producing at its prior fiscal yr finish.

• Elevated worker’s headcount from roughly 190 staff in Q1 2022 to 280 staff in Q1 2023; a 47% enhance, to assist the expansion of the operations.

• Cannara entered the British Columbia market with 7 of its dried flower, pre-roll, and hash merchandise.

• The Firm was deemed eligible to carry a hashish consultant registration by the province of Alberta in November 2022, paving the way in which for it to promote hashish into the Alberta retail market.

• Throughout the quarter, Cannara launched 14 new SKUs of its premium-grade hashish in Ontario and Quebec underneath the Firm’s flagship manufacturers: Tribal, Nugz and Orchid CBD, bringing its whole SKU depend to 32 SKUs. Included within the launch was:

• The Firm’s Nugz Recent Frozen Hash Rosin and Outdated College Hash have develop into prime 10 best-selling concentrates in Ontario¹.

• The Firm estimates its present market share as of the primary quarter of 2023 is roughly 7% in Quebec² and a pair of% in Ontario³.

Story continues

Gross sales and Operational Highlights Subsequent to Fiscal First Quarter 2023

• In December 2022, the Firm’s Farnham Facility acquired its CUMCS Equivalency IMC-G.A.P. certification (the “Certification”), a number one certification normal for medical hashish cultivation, harvest, and first processing. Acquiring the Certification offers documented proof that Cannara has met strict requirements for high quality and consistency within the cultivation, harvest and first processing of hashish wanted for export of hashish inputs to sure worldwide jurisdictions, together with Israel, Europe, and Australia.

• As a part of its advertising and marketing technique, the Firm designed and launched a number of traces of attire and equipment to be bought on-line at https://cannaraswag.store, together with Cannara’s hashish equipment: the Tribal UNI Professional Ark and the Nugz Häpple.

• In December 2022, the Firm was awarded three awards on the KIND Awards gala in Ontario highlighting the Firm’s concentrate on manufacturers and high-quality flower: The awards for Model of the 12 months and Terpene Profile of the 12 months got to Tribal, and CBD Runtz by Orchid CBD was named CBD Product of the yr.

• In December 2022, the Firm signed a lease settlement with a brand new tenant for a constructing that’s underneath building at its Valleyfield web site. The beginning of the lease time period is about for January 2024 with a time period of 11 years. This transaction will generate revenue and constructive money movement on an space of the Valleyfield Facility that will in any other case been unused as it’s not licensed for hashish manufacturing.

Capital Transactions

• Throughout the quarter, Cannara invested $3.7 million in capital expenditures which was primarily attributable to the activation of the 7^th rising zone, the development of a butane extraction lab, workplace and warehouse house, and preliminary prices associated to the processing middle construct out on the Valleyfield Facility, along with capital expenditures incurred ensuing from the anticipated elevated post-harvest necessities.

• On November 30, 2022, Cannara filed with the TSX Enterprise Alternate, a Discover in respect of a standard course issuer bid (the “NCIB”) to be transacted by way of the amenities of the TSX-V. Pursuant to the NCIB, Cannara might buy as much as 15,000,000 of its widespread shares. The Firm expects that the acquisition of Shares will profit remaining shareholders by growing their fairness curiosity within the Firm’s belongings.

• On January 12, 2023, The Firm introduced particulars of its proposal to consolidate all the issued and excellent widespread shares of the Firm on the idea of ten (10) pre-consolidation widespread shares for each one (1) post-consolidation widespread shares, topic to the approval of shareholders on the upcoming assembly of shareholders to happen on January 25, 2023, in addition to TSXV approval. Upon completion of the share consolidation, it’s anticipated that there shall be roughly 87,748,132 widespread shares issued and excellent, topic to adjustment for fractional shares.

• On January 20, 2023, the Firm granted a complete of 378,000 inventory choices at an train worth of $0.18, topic to sure vesting situations in accordance with the worker share choice plan.

“In Q1 2023, we continued to execute on Cannara’s development plan, as evidenced by the activation of our seventh develop zone at our Valleyfield Facility, our entry into the BC market and the discharge of 14 new high-demand SKU’s,” said Zohar Krivorot, President & Chief Government Officer of Cannara. “Now we have maintained our market share in Quebec, which we anticipate to extend in future quarters as we proceed to increase in Ontario, British Colombia, and Saskatchewan along with launching in Alberta. The discharge of 14 new SKU’s this quarter is a testomony to the onerous work of all Cannara employees right here and we’re assured that our premium merchandise will proceed to be a success with our ever-expanding buyer base,” concluded Mr. Krivorot.

Nicholas Sosiak, Chief Monetary Officer of Cannara added, “When in comparison with the earlier yr’s Q1 outcomes, the financials improved considerably throughout all metrics.  Nonetheless, we did expertise some short-term pre-roll manufacturing capability challenges that impacted gross sales throughout the quarter. We’re working diligently on growing inner pre-roll manufacturing capability, and we anticipate to renew our vital development pattern throughout Q2. We anticipate to attain 9 energetic rising zones at Valleyfield this yr, having simply activated our seventh, permitting us to higher volumes of premium-grade hashish. Because the Firm continues to scale, we anticipate revenues, margins, and earnings to proceed to enhance, and shareholders to be rewarded for his or her funding in Cannara. I’m proud to have the ability to report our seventh consecutive quarter of Adjusted EBITDA along with presently being on monitor to attaining report month-to-month gross sales in January 2023,” concluded Mr. Sosiak.

Chosen Monetary Data

Excellent Shares

As on the date of this report, the Firm had 877,481,321 widespread shares and 44,471,911 inventory choices issued and excellent. For additional info, the whole Consolidated Monetary Statements and Administration’s Dialogue and Evaluation, together with extra details about the Firm and all of its public filings which can be obtainable at sedar.com and the Firm’s investor web site, traders.cannara.ca.

About Cannara Biotech Inc.

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) is a vertically built-in producer of reasonably priced premium-grade hashish and cannabis-derivative merchandise for the Québec and Canadian markets. Cannara owns two mega amenities primarily based in Québec spanning over 1,650,000 sq. ft., offering the Firm with 120,000kg of potential annualized cultivation output. Leveraging Québec’s low electrical energy prices, Cannara’s amenities produce premium-grade hashish merchandise at an reasonably priced worth. For extra info, please go to cannara.ca.

Neither the TSX Enterprise Alternate nor its Regulation Companies Supplier (as that time period is outlined in insurance policies of the TSX Enterprise Alternate) accepts duty for the adequacy or accuracy of this launch.

Cautionary Assertion Concerning “Ahead-Trying” Data

This info launch incorporates sure forward-looking info. Such info includes identified and unknown dangers, uncertainties and different elements which will trigger precise outcomes, efficiency, or achievements to be materially totally different from these implied by statements herein, and due to this fact these statements shouldn’t be learn as ensures of future efficiency or outcomes. All forward-looking statements are primarily based on the Firm’s present beliefs in addition to assumptions made by and knowledge presently obtainable to it in addition to different elements. Readers are cautioned to not place undue reliance on these forward-looking statements, which communicate solely as of the date of this press launch. As a consequence of dangers and uncertainties, together with the dangers and uncertainties recognized by the Firm in its public securities filings, precise occasions might differ materially from present expectations. The Firm disclaims any intention or obligation to replace or revise any forward-looking statements, whether or not because of new info, future occasions or in any other case.

View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/cannara-biotech-inc-reports-q1-2023-financial-results-301727739.html

SOURCE Cannara Biotech Inc.

View unique content material to obtain multimedia: http://www.newswire.ca/en/releases/archive/January2023/23/c9524.html